We are live on ! Find out more
SEC

Seven Eight Capital Portfolio holdings

AUM $1.11B
1-Year Est. Return 29.48%
This Fund
S&P 500
This Quarter Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
Cap. Flow
+$327M
Cap. Flow %
38.29%
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$13.6M
2
MRK icon
Merck
MRK
+$12.5M
3
ISRG icon
Intuitive Surgical
ISRG
+$11.1M
4
DOCU
DocuSign
DOCU
+$10.9M
5
PODD icon
Insulet
PODD
+$10.8M

Sector Composition

Rank Sector Weight
1 Technology 20.41%
2 Consumer Discretionary 17.68%
3 Healthcare 16.13%
4 Industrials 12.13%
5 Financials 8.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
COR icon
101
Cencora
COR
$60.6B
$2.2M 0.26%
+12,200
New +$2.25M
ABBV icon
102
AbbVie
ABBV
$443B
$2.19M 0.26%
14,665
-33,739
-70% -$4.95M
BTU icon
103
Peabody Energy
BTU
$2.6B
$2.18M 0.26%
+83,950
New +$1.88M
STLA icon
104
Stellantis
STLA
$21.7B
$2.18M 0.26%
114,017
-42,642
-27% -$798K
PEP icon
105
PepsiCo
PEP
$190B
$2.11M 0.25%
+12,460
New +$2.26M
AMBA icon
106
Ambarella
AMBA
$3.77B
$2.09M 0.24%
+39,399
New +$2.77M
PANW icon
107
Palo Alto Networks
PANW
$270B
$2.08M 0.24%
+17,718
New +$2.1M
GT icon
108
Goodyear
GT
$2B
$2.07M 0.24%
166,729
-75,676
-31% -$1.03M
DDOG icon
109
Datadog
DDOG
$95.4B
$2.07M 0.24%
22,675
+17,165
+312% +$1.7M
CRDO icon
110
Credo Technology Group
CRDO
$38.6B
$2.04M 0.24%
+133,490
New +$2.11M
CNI icon
111
Canadian National Railway
CNI
$76.9B
$2.02M 0.24%
18,647
+14,899
+398% +$1.71M
PACB icon
112
Pacific Biosciences
PACB
$435M
$2.01M 0.24%
241,256
+221,353
+1,112% +$2.53M
TER icon
113
Teradyne
TER
$57.6B
$2.01M 0.23%
19,963
-35,024
-64% -$3.69M
GRMN
114
Garmin
GRMN
$56.7B
$1.99M 0.23%
18,881
+16,512
+697% +$1.74M
TDS icon
115
Telephone and Data Systems
TDS
$3.82B
$1.96M 0.23%
+107,254
New +$1.55M
SMAR
116
DELISTED
Smartsheet Inc.
SMAR
$1.92M 0.22%
+47,428
New +$1.95M
INFY icon
117
Infosys
INFY
$48.7B
$1.89M 0.22%
110,347
-82,413
-43% -$1.41M
SUM
118
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
$1.87M 0.22%
+60,080
New +$2.14M
PAGS icon
119
PagSeguro Digital
PAGS
$2.69B
$1.86M 0.22%
+216,069
New +$2.03M
STAA icon
120
STAAR Surgical
STAA
$1.21B
$1.85M 0.22%
46,167
+36,327
+369% +$1.7M
APO icon
121
Apollo Global Management
APO
$72.4B
$1.84M 0.21%
+20,473
New +$1.72M
GNRC icon
122
Generac Holdings
GNRC
$11.6B
$1.83M 0.21%
+16,818
New +$2.08M
SPWR
123
DELISTED
SunPower Corporation Common Stock
SPWR
$1.83M 0.21%
296,468
+70,964
+31% +$585K
TAL icon
124
TAL Education Group
TAL
$6.93B
$1.83M 0.21%
200,532
+52,217
+35% +$366K
CVX icon
125
Chevron
CVX
$392B
$1.83M 0.21%
+10,830
New +$1.75M

Similar funds

Seven Eight Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.

  • Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
  • Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
  • Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
  • Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
  • Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
  • Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
  • Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.

Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.